With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Women and men have the same rates of chest pain and other classic symptoms during ACS, although women are more likely to experience some other symptoms such as jaw and neck pain.
Edmonton, AB - Women are as likely as men to feel chest pain or other typical heart-attack symptoms, a study presented October 26, 2009 here at the Canadian Cardiovascular Congress 2009 shows [1].
In the study, presented by critical-care nurse Martha Mackay (University of British Columbia School of Nursing, Vancouver), 305 patients (39.7% women, average age 64) undergoing a nonemergent PCI were asked a series of open-ended questions about their sensations and experience while the angioplasty balloon was creating an ECG-evident ischemia.Read full article »
Inside: Acute Coronary Syndromes
Accredited educational programs,
supported by industry, developed by theheart.org
PLATO, CURRENT-OASIS 7, and further analyses of PPIs and thienopyridines; read Dr Prasad's review of recent data presented at ESC; and watch presentations by Drs Mehran, O'Donoghue, Storey, and Wiviott.
PLATO, CURRENT-OASIS 7, COGENT, recent meetings have seen some blockbuster presentations in the area of antiplatelet/antithrombotic therapy. What is your response to these data? Answer our 4 short polling questions and learn your peers' responses.
Patients presenting with STEMI represent a high-risk population. Thrombotic and bleeding complications contribute to mortality in these patients. Join Drs. Steg, Hamm, Hill, and Mehran as they discuss best practices for the treatment of STEMI patients with a focus on preventing bleeding complications.
In the US, each year over 1.4 million people will be hospitalized for unstable angina (UA) and non-ST-segment-elevation myocardial infarction (NSTEMI). Multiple antiplatelet agents have been developed to interfere with or inhibit the specific pathways of platelet activation and aggregation that lead to the development of UA and NSTEMI. Join Drs Newby, Popma, and Wiviot as they discuss.
Join Drs. Cannon, Gupta, Schampaert, and Le May as they discuss how data stemming from recent clinical trials are adding up for ACS patients in Canada intended for PCI. They review how clinical decision-making based on efficacy, safety, and patient profile is changing in light of antiplatelet therapies that are currently available and those that may be available in the near future.
What new antiplatelet treatment options are on the horizon for ACS patients in Canada? Drs. Harrington, Goodman, Tanguay, and Welsh do the math using new clinical data to assess pharmacologic, safety, and patient profiles, and address the potential implications for the future of antiplatelet therapy in Canada.
What's the latest clinical evidence for efficacy and safety of dual antiplatelet therapy loading and maintenance dosage for ACS patients? Join Drs. Tanguay, Eikelboom, Mehta, and Welsh as they discuss the latest clinical data and the potential impact on ACS treatment, and Canadian guidelines.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
The latest recommendations for the treatment of ST-elevation MI issued by American cardiology associations and the European Society of Cardiology are compared and contrasted in a new paper.
The imaging study was the first to show that stenting a non-flow-limiting stenosis of an SVG may help slow or halt the accelerated atherosclerosis that takes place in these vessels. An accompanying editorial cautions that the study does little more than "infer a trend toward anatomic benefit."
UPDATED // An 1126-patient trial shows that SPECT and CAC scoring imaging tests are independent and complementary predictors of short- and long-term cardiac risk, respectively.
A US update on the perioperative use of beta blockers for noncardiac surgery is, says the lead author, "similar" to recent European guidance on this issue.
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumes—the more commonly seen end point with MRI.
Inflammatory responses contribute to coronary plaque rupture, thrombosis, and vascular occlusion. Some viruses have proteins that interfere with these inflammatory responses. Researchers have identified a viral-derived protein that may eventually be an anti-inflammatory treatment for coronary syndromes.
Two well-known observational registries highlight such changes in women and men over a decade or more: Do women younger than 55 still have an advantage over men in the same age group?
After a median follow-up of 12 years, MI rates were essentially the same among those treated with surgery and those who received conventional care for weight loss.
A new analysis of national registry data suggests that the superior outcomes of NSTEMI patients in hospitals with open-heart-surgery capabilities vs those without it are due to their size, procedure volume, and adherence to medication guidelines.
Pericardial fat, which is found around the heart, predicts future CHD events and may even be a better predictor of these than conventional obesity measures, such as BMI and waist circumference, a new study of MESA participants shows.
Intravenously administered iloprost, a prostacyclin analog, may help prevent contrast-induced nephropathy in patients with renal dysfunction undergoing coronary procedures, a new pilot study suggests.
The role of lipids in women for primary prevention of cardiovascular disease is a challenging issue for all providers. Join Drs. Foody, Mora, and Welty as they discuss limitations to current risk stratification models, recent clinical trial data, and the changing paradigm in the management of lipids in women.
We know there are sex and biological differences in the manifestation of CVD. How do these pathophysiological differences affect the diagnosis and treatment of our female patients? Drs. Hayes, Johnson, Manson, and Piña provide their insight.
Despite increased awareness of CVD in women, contemporary studies demonstrate gender differences in outcomes. Differences in age and comorbidities account for some, but not all of these disparities. Join Dr. Foody as she discusses these issues with Drs. Mieres and Redberg.
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Dr Melissa Walton-Shirley talks to Dr Nassir Marrouche about the results of RE-LY, the impact of dronedarone on the treatment of atrial fibrillation, and his hopes for the future of MRI-guided ablation.
Drs. Hayes and Foody and a committee of experts address the gaps and correct the misconception that CVD is more common in men than women.